These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12648034)

  • 1. The economic burden of stroke in the United Kingdom.
    Youman P; Wilson K; Harraf F; Kalra L
    Pharmacoeconomics; 2003; 21 Suppl 1():43-50. PubMed ID: 12648034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated societal costs of stroke in the UK based on a discrete event simulation.
    Patel A; Berdunov V; Quayyum Z; King D; Knapp M; Wittenberg R
    Age Ageing; 2020 Feb; 49(2):270-276. PubMed ID: 31846500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of stroke in the United Kingdom.
    Saka O; McGuire A; Wolfe C
    Age Ageing; 2009 Jan; 38(1):27-32. PubMed ID: 19141506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial and health costs of uncontrolled blood pressure in the United Kingdom.
    Lloyd A; Schmieder C; Marchant N
    Pharmacoeconomics; 2003; 21 Suppl 1():33-41. PubMed ID: 12648033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cost-effectiveness of thrombectomy for acute ischaemic stroke in real life: An analysis based on data from the Swedish Stroke Register (Riksstroke).
    Steen Carlsson K; Andsberg G; Petersson J; Norrving B
    Int J Stroke; 2017 Oct; 12(8):802-814. PubMed ID: 28375069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of patients admitted to stroke units in Spain.
    Alvarez-Sabín J; Quintana M; Masjuan J; Oliva-Moreno J; Mar J; Gonzalez-Rojas N; Becerra V; Torres C; Yebenes M;
    Eur J Health Econ; 2017 May; 18(4):449-458. PubMed ID: 27084749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
    Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
    Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and disability among stroke patients.
    Kavanagh S; Knapp M; Patel A
    J Public Health Med; 1999 Dec; 21(4):385-94. PubMed ID: 11469359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial.
    Patel A; Knapp M; Perez I; Evans A; Kalra L
    Stroke; 2004 Jan; 35(1):196-203. PubMed ID: 14684783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
    Chambers M; Hutton J; Gladman J
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Training care givers of stroke patients: economic evaluation.
    Patel A; Knapp M; Evans A; Perez I; Kalra L
    BMJ; 2004 May; 328(7448):1102. PubMed ID: 15130978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.
    Plumb JM; Guest JF
    Pharmacoeconomics; 2000 Nov; 18(5):477-86. PubMed ID: 11151401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).
    Clarke P; Gray A; Legood R; Briggs A; Holman R
    Diabet Med; 2003 Jun; 20(6):442-50. PubMed ID: 12786677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of post-acute myocardial infarction heart failure in the United Kingdom.
    Lacey L; Tabberer M
    Eur J Heart Fail; 2005 Jun; 7(4):677-83. PubMed ID: 15921811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event.
    Tavakoli M; Pumford N; Woodward M; Doney A; Chalmers J; MacMahon S; Macwalter R
    Eur J Health Econ; 2009 Feb; 10(1):111-9. PubMed ID: 18446392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden of stroke in Italy: an economic model highlights savings arising from reduced disability following thrombolysis.
    Chiumente M; Gianino MM; Minniti D; Mattei TJ; Spass B; Kamal KM; Zimmerman DE; Muca A; Luda E
    Int J Stroke; 2015 Aug; 10(6):849-55. PubMed ID: 25854294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.